Pegargiminase Explained
| Cas Number: | 1394129-74-8 |
| Pubchemsubstance: | 194189083 |
| Drugbank: | DB06592 |
| Unii: | 0B7PYQ9YRT |
| Chembl: | 3137346 |
| Synonyms: | ADI-PEG20 |
Pegargiminase (also known as pegylated arginine deiminase) is an investigational drug used in arginine deprivation therapy for treating cancers deficient in argininosuccinate synthetase 1 (ASS1).[1] [2] [3] [4] It is a recombinant form of the enzyme arginine deiminase cloned from the bacteria Mycoplasma hominus and synthesized in Escherichia coli. It has been pegylated to improve the half-life and reduce immunogenicity.
Notes and References
- Feun L, Savaraj N . Pegylated arginine deiminase: a novel anticancer enzyme agent . Expert Opinion on Investigational Drugs . 15 . 7 . 815–22 . July 2006 . 16787144 . 3086545 . 10.1517/13543784.15.7.815 .
- Kuo MT, Savaraj N, Feun LG . Targeted cellular metabolism for cancer chemotherapy with recombinant arginine-degrading enzymes . Oncotarget . 1 . 4 . 246–51 . August 2010 . 21152246 . 2998341 . 10.18632/oncotarget.135 .
- Synakiewicz A, Stachowicz-Stencel T, Adamkiewicz-Drozynska E . The role of arginine and the modified arginine deiminase enzyme ADI-PEG 20 in cancer therapy with special emphasis on Phase I/II clinical trials . Expert Opinion on Investigational Drugs . 23 . 11 . 1517–29 . November 2014 . 24965808 . 10.1517/13543784.2014.934808 .
- Field GC, Pavlyk I, Szlosarek PW . Bench-to-Bedside Studies of Arginine Deprivation in Cancer . Molecules . Basel, Switzerland . 28 . 5 . February 2023 . 2150 . 36903394 . 10005060 . 10.3390/molecules28052150 . free .
